U.S. FDA receives ONS-5010 Biologics License Application from Outlook Therapeutics

U.S. FDA receives ONS-5010 Biologics License Application from Outlook Therapeutics
Outlook resubmits FDA application

Outlook Therapeutics has announced the resubmission of its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg), a therapy candidate aimed at treating retina diseases such as wet age-related macular degeneration.

This move comes amid growing demand for new treatments in ophthalmology, with ONS-5010 potentially providing an alternative option for patients suffering from vision impairment related to retinal conditions. The U.S. FDA review will determine whether ONS-5010 can move forward toward market approval.

Outlook Therapeutics recently launched a registered direct offering priced at the market under Nasdaq rules. Earlier this year, the company won an appeal tied to ONS-5010 LYTENAVA through a formal dispute resolution process. These developments have supported ongoing product progress.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.